Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740890 | 0.84 | TTR (0.46) | LMNAKMT2A | |
| SCHEMBL16742340 | 0.83 | PKM (0.37) | LMNANOTUMSMN1; SMN2CA12CA1 | |
| SCHEMBL30708145 | 0.83 | KMT2A (0.46) | LMNAKDM4EKMT2AMAPTRAB9A | |
| SCHEMBL644389 | 0.83 | KMT2A (0.46) | LMNAKDM4EKMT2AMAPTRAB9A | |
| SCHEMBL16742155 | 0.83 | NOTUM (0.35) | LMNANOTUMSMN1; SMN2CA12CA1 | |
| SCHEMBL7155489 | 0.78 | PDK2 (0.39) | LMNANOTUMSMN1; SMN2CA12CA1 | |
| SCHEMBL2428416 | 0.77 | LMNA (0.39) | LMNASMN1; SMN2KDM4EGAAKMT2A | |
| SCHEMBL15947259 | 0.74 | MAPT (0.47) | LMNASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL31417679 | 0.74 | NOTUM (0.40) | LMNANOTUMSMN1; SMN2CA12CA1 | |
| SCHEMBL30329839 | 0.74 | NOTUM (0.40) | LMNANOTUMSMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822103-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822103-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822103-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297805-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297805-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297805-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077194-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077194-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1726580-A1 | AMINOPHENYLPROPANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | EZH2, DOT1L, EHMT1 | LMNA 3571/4885NOTUM 2352/4885SMN1; SMN2 4156/4885 |
| US-20160297805-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | EZH2, DOT1L, EHMT1 | LMNA 3548/4885NOTUM 2284/4885SMN1; SMN2 4155/4885 |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | GPR119, GPR55, GPR65 | LMNA 4270/4885NOTUM 3128/4885SMN1; SMN2 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.